Summit Looking To Secure Superiority Claim For Ridinilazole Over Vancomycin In C. Diff

 
• By Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

Company’s Phase III program is attempting to replicate Phase II efficacy data showing superiority for curing Clostridium difficile infections and preventing recurrence, while also compiling health economics data.

Bacteria
Summit thinks narrow-spectrum therapy is the best way to fight C. diff infections

Summit Therapeutics PLC says the goal for its novel antibiotics is to “cure the patient and keep them cured.” Under that banner, the company's ridinilazole, its Phase III candidate for Clostridium difficile infections, is being positioned as a better therapeutic option than the broad-spectrum antibiotic vancomycin, because its narrow-spectrum effect targets C. diff imbalance while leaving the rest of a patient’s microbiome undisturbed, reducing the likelihood of infection recurrence.

Summit chief operating officer David Roblin said in an interview during the Infectious Disease Society of America’s IDWeek conference on...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By Xu Hu

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By Xu Hu

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D